Background

Cancer is one of the leading causes of death worldwide causing approximately 1 in every 7 deaths. In 2012, 8.2 million people died of the disease with 14 million new cases recorded in that year (WHO Figures). In 2030, the number of new cancer cases is projected to be >22 million (50-70% increase) due to the increasing population age and size.

Cancer immunotherapy (active and passive) aims to harness the body’s own immune system in the fight against tumour progression. In the past decade, this strategy has become the most promising in the search for novel cancer therapies. Recent breakthroughs include either tumour specific/bi-specific monoclonal antibodies (mAbs), checkpoint inhibitors, adoptive cell therapy and therapeutic cancer vaccines (peptides, dendritic cells, allogenic cells, autologous cells, oncolytic viruses). For the latter group, Dendreon’s Provenge® (Sipuleucel-T) was the first therapeutic vaccine approved for any cancer.

This MarketVIEW product consists of a detailed Executive presentation (~100 slides) and MS-Excel work book summarizing current approaches in cancer immunotherapy with an in-depth focus on the therapeutic cancer vaccine category. Included is an analysis of over 300 verified cancer vaccine programs (Phase I-III) delineated by sponsor, sponsor type, mechanism, tumor type, results, and other relevant fields. Detailed case studies are presented for the identified late stage (Phase III) industry sponsored programs e.g. PROSTVAC® Bavarian Nordic with presentation of clinical trial data relevant to the Provenge® (Sipuleucel-T) reference for FDA approval. This analysis is recommended to any client wishing to understand quickly the commercial landscape of the therapeutic cancer vaccine field within the overview dynamic of cancer immunotherapy.
Methodology

**VacZine Analytics** has closely monitored all significant source material pertaining to therapeutic cancer vaccines as approaches to cancer immunotherapy. Source materials used are literature articles, government websites, medical bodies and associations, conference proceedings etc.

**PRODUCT CONTENTS:**

Published February 2017 (CAT No: VAMV072)

****This product is composed of **one Excel workbook (.xls)** and **an executive presentation (.pdf)**

**Contents**

- Executive summary
- Cancer and immunotherapy
- Cancer immunotherapy: broad approaches
- Overview
- Introduction to cancer vaccines
- Types of cancer vaccines
- Cancer vaccine approaches: cell-based vaccines
- Cancer vaccine approaches: peptide-based vaccines
- Cancer vaccine approaches: DNA vaccines
- Cancer vaccine approaches: RNA vaccines
- Cancer vaccine approaches: Viral vector vaccines
- Cancer vaccine approaches: Oncolytic viruses
- Approved therapeutic cancer vaccines
- Provenge® ( sipuleucel-T )
- Provenge® ( sipuleucel-T ): Phase III data
- Provenge® ( sipuleucel-T ): Ongoing trials
- Current R&D pipeline
- Cancer vaccines: pipeline analysis methodology
- Cancer vaccine trials (Phase I-III), by tumour type
- Cancer vaccine trials, by phase and sponsor type 2016
- Cancer vaccine trials, by tumour and sponsor type 2016
- Cancer vaccine trial phases verified 2016 per tumour tissue
- Cancer vaccine phase III trials per tumour type
- Cancer vaccine trials conducted for single vs multiple tissue tumours - verified in 2016
- Industry sponsored Phase II/III and Phase III cancer vaccine trials verified in 2016
- Melanoma
  - Seviprotimut-L (POL-103A) - Polynoma
  - Seviprotimut-L (POL-103A): Phase II data
- Prostate Cancer
  - PROSTVAC® (rilimogene galvacirepvac) - Bavarian Nordic
  - PROSTVAC®: Phase II data
  - PROSTVAC®: Phase III trial (ongoing)
  - PROSTVAC®: Key ongoing trials
  - ProstAtak® (AdV-tk) - Advantagene Inc
  - ProstAtak® (AdV-tk): Phase II trial
  - DCVAC/PCa - Sotio

---

1 Contents available on request
2 Presentation titles may apply to more than one slide
Continued……

DCVAC/PCa: Phase II data
DCVAC/PCa: Key ongoing trials
Brain Cancer
DCVax®-L: Northwest Biotherapeutics
DCVax®-L: Phase II/II DCVax-L Trials
DCVax®-L: Key ongoing trials
ICT-107 - Immunocellular Therapeutics Ltd
ICT-107: Phase II data
Ovarian Cancer
Vigi® (gemogenovatucel-T, FANGTM) - Gradalis
Vigi®: Phase II data
Vigi®: Key ongoing trials
Colon Cancer
ALLOSTIM® - Immunovative Therapies Ltd
ALLOSTIM®: Phase I/II data
ALLOSTIM®/Allovax®: Key ongoing trials
Lung Cancer
Tedopi® (OSE2101) - OSE Immunotherapeutics
Tedopi® (OSE-2101, IDM-2101): Phase II data
Vaxira® (Racotumomab-alum, 1E10) - Reombio
Vaxira® (Racotumomab-alum, 1E10): Phase II data
EGF PTI (BV-NSCLC-002) - Bioven
EGF PTI (BV-NSCLC-002): Phase II data
HyperAcuteTM (Tergenpumatucel-L) - NewLink Genetics Corporation
HyperAcuteTM (Tergenpumatucel-L): Phase II study
Appendix: Historical analysis since 1991
Cancer vaccine trials to date: Historical view since 1991
Cancer vaccine trials to date - Result status historical view
Cancer Vaccine Trials to Date - Trial phase historical view
Cancer Vaccine Trials to Date - Trials conducted for single vs multiple tissue tumours - historical view
Cancer vaccine trials - Last verification dates
Cancer vaccine trials - Last verification dates 2001-2016 by tissue
Cancer vaccines: development history summary

Slide number = 99
PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- FULL PRODUCT - USD $6995.00/ GBP £5780.00* (Region license)*

*Indicative company rate only. Prevailing rate applied to date of transaction.
*A region is North America, Europe or ROW
For orders in the UK, VAT at 20.0% will be added to final invoice total
Agency/consultancy rates (commercial use) are available upon request

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com
This report can also be purchased on-line. Please review the TERMS and CONDITIONS of purchase.
BIBLIOGRAPHY

13. Peptide Based Vaccine Approaches for Cancer—A Novel Approach Using a WT-1 Synthetic Long Peptide and the IRX-2 Immunomodulatory Regimen, Naylor et al, Cancers 2013, 3, 3991-4009
47. The anti-tumor effect of an allogeneic bone marrow/ stem cell transplant without graft vs. host disease toxicity and without a matched donor requirement? Har-Noy and Slavin. Medical Hypotheses (2008) 70, 1186–1192
TERMS and CONDITIONS:
VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. This finished research product is provided is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.
2. The Service will commence after written (e-mail) or Fax confirmation stating the Client’s acceptance of the Service according the description proposed by the Company.
3. Cancellation policy. The Company’s cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.
4. Cancellation rights: For finished documents - a Clients cancellation rights will last for seven working days counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client’s cancellation rights have ended.
5. Invoicing will 100% after submission of deliverables to the Client in a form reasonably acceptable to the Client.
6. If not purchased on line invoices are payable within thirty days of the invoice date.
7. All proposals are quoted in $USD dollars or £GBP and invoices are to be settled in the same currency.
8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company’s employees and agents with the performance of the Company’s obligations to achieve satisfactory completion of the project and approved in writing by the Client.
9. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
10. Please also refer to Master TERMS and CONDITIONS available upon request.

VacZine Analytics
Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 813155
E-mail: info@vacZine-analytics.com
About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website [www.vacZine-analytics.com](http://www.vacZine-analytics.com)

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728
VacZine Analytics (R) and “the spiral logo” are UK Registered Trademarks, 2009